AMS questionnaire

The AMS questionnaire itself (or any other questionnaire) does not constitute a test or diagnosis of hypogonadism (also known as testosterone deficiency). A diagnosis of hypogonadism is based on symptoms that are indicative of testosterone deficiency (the AMS questionnaire can be used for symptom evaluation), combined with low testosterone levels as detected by mandatory blood testing.1-4

The AMS scale is comparable to other scales for aging males or screening instruments for testosterone deficiency, and thus can be used to identify symptomatic men who should be investigated further with a blood test of testosterone.7 It is commonly used as part of the diagnosis of hypogonadism, which requires the presence of characteristic symptoms and signs in combination with low serum levels of testosterone.8-11 

The AMS scale is also a valuable tool to measure effects of testosterone treatment on symptom relief over time.15,16 

In addition, the AMS scale can help you to “break the ice” at you first doctor visit, as it specifically asks for symptoms that you would not otherwise spell out, but that have an important impact on your wellbeing and quality of life.

On the last page of the questionnaire you will get the option to print out your AMS score. We suggest you do, and bring it to your doctor.

For more information about the AMS questionnaire, and all its validated language versions, visit http://zeg-berlin.de/expertise/diagnostics-tools/aging-male-symptoms-scale/about-ams-scale/

Disclaimer: This is for general information only and is not intended to replace a consultation with a healthcare professional, nor is it intended to provide specific medical advice and should not be used for the diagnosis or treatment of medical conditions.

Recommendations

Long term therapy with Nebido®

Waist-to-height ratio

References

  1. Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S, Punab M. 2016 EAU Guidelines on Male Hypogonadism, available at http://uroweb.org/wp-content/uploads/EAU-Guidelines-Male-Hypogonadism-2016.pdf (accessed January 11, 2017).
  2. Dean JD, McMahon CG, Guay AT, et al. The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. The journal of sexual medicine. 2015;12(8):1660-1686.
  3. Morales A, Bebb RA, Manjoo P, et al. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. Appendix available at: http://www.cmaj.ca/content/suppl/2015/10/26/cmaj.150033.DC1/15-0033-1-at.pdf (accessed Jan 10, 2016). CMAJ. 2015;187(18):1369-1377.
  4. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2010;95(6):2536-2559.
  5. Heinemann LA, Saad F, Zimmermann T, et al. The Aging Males' Symptoms (AMS) scale: update and compilation of international versions. Health and quality of life outcomes. 2003;1:15.
  6. Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel. C. A new ‘Aging Male’s Symptoms’ (AMS) rating scale. The aging male : the official journal of the International Society for the Study of the Aging Male. 1999;2:105–114.
  7. Daig I, Heinemann LA, Kim S, et al. The Aging Males' Symptoms (AMS) scale: review of its methodological characteristics. Health and quality of life outcomes. 2003;1:77.
  8. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. The aging male : the official journal of the International Society for the Study of the Aging Male. 2015;18(1):5-15.
  9. Dean JD, McMahon CG, Guay AT, et al. The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. The journal of sexual medicine. 2015;12(8):1660-1686.
  10. Morales A, Bebb RA, Manjoo P, et al. Multidisciplinary Canadian Clinical Practice Guideline on the Diagnosis and Management of Testosterone Deficiency Syndrome in Adult Males. CMAJ. 2015.
  11. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J. Clin. Endocrinol. Metab. 2006;91(11):4335-4343.
  12. Carruthers M. The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action. The journal of sexual medicine. 2008;5(4):998-1012.
  13. Collier CP, Morales A, Clark A, Lam M, Wynne-Edwards K, Black A. The significance of biological variation in the diagnosis of testosterone deficiency, and consideration of the relevance of total, free and bioavailable testosterone determinations. J. Urol. 2010;183(6):2294-2299.
  14. Morgentaler A, Khera M, Maggi M, Zitzmann M. Commentary: who is a candidate for testosterone therapy? A synthesis of international expert opinions. The journal of sexual medicine. 2014;11(7):1636-1645.
  15. Heinemann LA, Moore C, Dinger JC, Stoehr D. Sensitivity as outcome measure of androgen replacement: the AMS scale. Health and quality of life outcomes. 2006;4:23.
  16. Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur. Urol. 2004;46(1):80-87.
  • PP-NEB-ALL-0347-1

Copyright © 2019,
Bayer AG

This website is intended to provide information to an international audience outside the USA and UK.

Page last modified Mon, 16/09/2019

Bayer logo